{"id":18243,"date":"2014-09-11T11:14:27","date_gmt":"2014-09-11T11:14:27","guid":{"rendered":"https:\/\/www.editage.com\/insights\/research\/induced-pluripotent-stem-cell-treatment-set-for-its-first-human-trial\/"},"modified":"2025-09-19T16:11:07","modified_gmt":"2025-09-19T10:41:07","slug":"induced-pluripotent-stem-cell-treatment-set-for-its-first-human-trial","status":"publish","type":"research","link":"https:\/\/www.editage.com\/insights\/induced-pluripotent-stem-cell-treatment-set-for-its-first-human-trial","title":{"rendered":"Induced pluripotent stem cell treatment set for its first human trial"},"content":{"rendered":"<p style=\"text-align: justify;\"><span style=\"font-family: verdana,geneva,sans-serif;\"><span style=\"font-size: 14px;\">Masayo Takahashi, an ophthalmologist at the RIKEN Center for Developmental Biology (CDB) in Kobe, is set to treat a human patient with induced pluripotent stem (iPS) cells. iPS cells, unlike embryonic stem cells, are developed from adult cells and are capable of becoming any type of cell in the body. The biggest advantage of iPS cells is that they can be genetically tailored to each individual and can be used to treat various diseases. For the first time, this technology will be used to treat age-related macular degeneration. Takashashi converted skin cells from her patient into iPS cells, which she then converted into retinal pigment epithelium cells; these cells will be transplanted into the patient\u2019s damaged retina. A health-ministry committee has confirmed that this treatment will not provoke an immune reaction and mutations of any kind, and has approved its trial in humans.\u00a0<\/span><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-family: verdana,geneva,sans-serif;\"><span style=\"font-size: 14px;\">Read more in <a href=\"http:\/\/www.nature.com\/news\/next-generation-stem-cells-cleared-for-human-trial-1.15897\">Nature<\/a>.\u00a0<\/span><\/span><\/p>\n<p style=\"text-align: justify;\"><em><span style=\"font-family: verdana,geneva,sans-serif;\"><span style=\"font-size: 14px;\">Update: The surgery was successfully performed on a Japanese woman in her 70s on September 12. See details <a href=\"http:\/\/www.nature.com\/news\/japanese-woman-is-first-recipient-of-next-generation-stem-cells-1.15915\">here<\/a>.\u00a0<\/span><\/span><\/em><\/p>\n","protected":false},"author":8,"featured_media":33313,"template":"","meta":{"_acf_changed":false,"inline_featured_image":false},"new_tags":[],"series":[],"subject":[2976,2974,2975],"class_list":["post-18243","research","type-research","status-publish","has-post-thumbnail","hentry","subject-and-molecular-biology","subject-biochemistry","subject-genetics"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Induced pluripotent stem cell treatment set for its first human trial | Editage Insights<\/title>\n<meta name=\"description\" content=\"Masayo Takahashi, an ophthalmologist at the RIKEN Center for Developmental Biology (CDB) in Kobe, is set to treat a human patient with induced pluripotent stem (iPS) cells. Read on to find out more.\u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.editage.com\/insights\/induced-pluripotent-stem-cell-treatment-set-for-its-first-human-trial\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Induced pluripotent stem cell treatment set for its first human trial | Editage Insights\" \/>\n<meta property=\"og:description\" content=\"Masayo Takahashi, an ophthalmologist at the RIKEN Center for Developmental Biology (CDB) in Kobe, is set to treat a human patient with induced pluripotent stem (iPS) cells. Read on to find out more.\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.editage.com\/insights\/induced-pluripotent-stem-cell-treatment-set-for-its-first-human-trial\" \/>\n<meta property=\"og:site_name\" content=\"Editage Insights\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/Editage\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-19T10:41:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.editage.com\/insights\/wp-content\/uploads\/2025\/06\/editage-insights-generic-banner.png\" \/>\n\t<meta property=\"og:image:width\" content=\"870\" \/>\n\t<meta property=\"og:image:height\" content=\"446\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@Editage\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.editage.com\/insights\/induced-pluripotent-stem-cell-treatment-set-for-its-first-human-trial\",\"url\":\"https:\/\/www.editage.com\/insights\/induced-pluripotent-stem-cell-treatment-set-for-its-first-human-trial\",\"name\":\"Induced pluripotent stem cell treatment set for its first human trial | Editage Insights\",\"isPartOf\":{\"@id\":\"https:\/\/www.editage.com\/insights\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.editage.com\/insights\/induced-pluripotent-stem-cell-treatment-set-for-its-first-human-trial#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.editage.com\/insights\/induced-pluripotent-stem-cell-treatment-set-for-its-first-human-trial#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.editage.com\/insights\/wp-content\/uploads\/2025\/02\/editage-insights-generic-banner_298.webp\",\"datePublished\":\"2014-09-11T11:14:27+00:00\",\"dateModified\":\"2025-09-19T10:41:07+00:00\",\"description\":\"Masayo Takahashi, an ophthalmologist at the RIKEN Center for Developmental Biology (CDB) in Kobe, is set to treat a human patient with induced pluripotent stem (iPS) cells. Read on to find out more.\u00a0\",\"breadcrumb\":{\"@id\":\"https:\/\/www.editage.com\/insights\/induced-pluripotent-stem-cell-treatment-set-for-its-first-human-trial#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.editage.com\/insights\/induced-pluripotent-stem-cell-treatment-set-for-its-first-human-trial\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.editage.com\/insights\/induced-pluripotent-stem-cell-treatment-set-for-its-first-human-trial#primaryimage\",\"url\":\"https:\/\/www.editage.com\/insights\/wp-content\/uploads\/2025\/02\/editage-insights-generic-banner_298.webp\",\"contentUrl\":\"https:\/\/www.editage.com\/insights\/wp-content\/uploads\/2025\/02\/editage-insights-generic-banner_298.webp\",\"width\":656,\"height\":336},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.editage.com\/insights\/induced-pluripotent-stem-cell-treatment-set-for-its-first-human-trial#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.editage.com\/insights\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Researchs\",\"item\":\"https:\/\/www.editage.com\/insights\/research\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Induced pluripotent stem cell treatment set for its first human trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.editage.com\/insights\/#website\",\"url\":\"https:\/\/www.editage.com\/insights\/\",\"name\":\"Editage Insights\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.editage.com\/insights\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.editage.com\/insights\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.editage.com\/insights\/#organization\",\"name\":\"Editage Insights\",\"url\":\"https:\/\/www.editage.com\/insights\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.editage.com\/insights\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.editage.com\/insights\/wp-content\/uploads\/2024\/09\/editage-insights-logo-1-scaled.webp\",\"contentUrl\":\"https:\/\/www.editage.com\/insights\/wp-content\/uploads\/2024\/09\/editage-insights-logo-1-scaled.webp\",\"width\":2560,\"height\":324,\"caption\":\"Editage Insights\"},\"image\":{\"@id\":\"https:\/\/www.editage.com\/insights\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Editage\",\"https:\/\/x.com\/Editage\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Induced pluripotent stem cell treatment set for its first human trial | Editage Insights","description":"Masayo Takahashi, an ophthalmologist at the RIKEN Center for Developmental Biology (CDB) in Kobe, is set to treat a human patient with induced pluripotent stem (iPS) cells. Read on to find out more.\u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.editage.com\/insights\/induced-pluripotent-stem-cell-treatment-set-for-its-first-human-trial","og_locale":"en_US","og_type":"article","og_title":"Induced pluripotent stem cell treatment set for its first human trial | Editage Insights","og_description":"Masayo Takahashi, an ophthalmologist at the RIKEN Center for Developmental Biology (CDB) in Kobe, is set to treat a human patient with induced pluripotent stem (iPS) cells. Read on to find out more.\u00a0","og_url":"https:\/\/www.editage.com\/insights\/induced-pluripotent-stem-cell-treatment-set-for-its-first-human-trial","og_site_name":"Editage Insights","article_publisher":"https:\/\/www.facebook.com\/Editage","article_modified_time":"2025-09-19T10:41:07+00:00","og_image":[{"width":870,"height":446,"url":"https:\/\/www.editage.com\/insights\/wp-content\/uploads\/2025\/06\/editage-insights-generic-banner.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Editage","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.editage.com\/insights\/induced-pluripotent-stem-cell-treatment-set-for-its-first-human-trial","url":"https:\/\/www.editage.com\/insights\/induced-pluripotent-stem-cell-treatment-set-for-its-first-human-trial","name":"Induced pluripotent stem cell treatment set for its first human trial | Editage Insights","isPartOf":{"@id":"https:\/\/www.editage.com\/insights\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.editage.com\/insights\/induced-pluripotent-stem-cell-treatment-set-for-its-first-human-trial#primaryimage"},"image":{"@id":"https:\/\/www.editage.com\/insights\/induced-pluripotent-stem-cell-treatment-set-for-its-first-human-trial#primaryimage"},"thumbnailUrl":"https:\/\/www.editage.com\/insights\/wp-content\/uploads\/2025\/02\/editage-insights-generic-banner_298.webp","datePublished":"2014-09-11T11:14:27+00:00","dateModified":"2025-09-19T10:41:07+00:00","description":"Masayo Takahashi, an ophthalmologist at the RIKEN Center for Developmental Biology (CDB) in Kobe, is set to treat a human patient with induced pluripotent stem (iPS) cells. Read on to find out more.\u00a0","breadcrumb":{"@id":"https:\/\/www.editage.com\/insights\/induced-pluripotent-stem-cell-treatment-set-for-its-first-human-trial#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.editage.com\/insights\/induced-pluripotent-stem-cell-treatment-set-for-its-first-human-trial"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.editage.com\/insights\/induced-pluripotent-stem-cell-treatment-set-for-its-first-human-trial#primaryimage","url":"https:\/\/www.editage.com\/insights\/wp-content\/uploads\/2025\/02\/editage-insights-generic-banner_298.webp","contentUrl":"https:\/\/www.editage.com\/insights\/wp-content\/uploads\/2025\/02\/editage-insights-generic-banner_298.webp","width":656,"height":336},{"@type":"BreadcrumbList","@id":"https:\/\/www.editage.com\/insights\/induced-pluripotent-stem-cell-treatment-set-for-its-first-human-trial#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.editage.com\/insights\/"},{"@type":"ListItem","position":2,"name":"Researchs","item":"https:\/\/www.editage.com\/insights\/research"},{"@type":"ListItem","position":3,"name":"Induced pluripotent stem cell treatment set for its first human trial"}]},{"@type":"WebSite","@id":"https:\/\/www.editage.com\/insights\/#website","url":"https:\/\/www.editage.com\/insights\/","name":"Editage Insights","description":"","publisher":{"@id":"https:\/\/www.editage.com\/insights\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.editage.com\/insights\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.editage.com\/insights\/#organization","name":"Editage Insights","url":"https:\/\/www.editage.com\/insights\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.editage.com\/insights\/#\/schema\/logo\/image\/","url":"https:\/\/www.editage.com\/insights\/wp-content\/uploads\/2024\/09\/editage-insights-logo-1-scaled.webp","contentUrl":"https:\/\/www.editage.com\/insights\/wp-content\/uploads\/2024\/09\/editage-insights-logo-1-scaled.webp","width":2560,"height":324,"caption":"Editage Insights"},"image":{"@id":"https:\/\/www.editage.com\/insights\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Editage","https:\/\/x.com\/Editage"]}]}},"_links":{"self":[{"href":"https:\/\/www.editage.com\/insights\/wp-json\/wp\/v2\/research\/18243","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.editage.com\/insights\/wp-json\/wp\/v2\/research"}],"about":[{"href":"https:\/\/www.editage.com\/insights\/wp-json\/wp\/v2\/types\/research"}],"author":[{"embeddable":true,"href":"https:\/\/www.editage.com\/insights\/wp-json\/wp\/v2\/users\/8"}],"version-history":[{"count":0,"href":"https:\/\/www.editage.com\/insights\/wp-json\/wp\/v2\/research\/18243\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.editage.com\/insights\/wp-json\/wp\/v2\/media\/33313"}],"wp:attachment":[{"href":"https:\/\/www.editage.com\/insights\/wp-json\/wp\/v2\/media?parent=18243"}],"wp:term":[{"taxonomy":"new_tags","embeddable":true,"href":"https:\/\/www.editage.com\/insights\/wp-json\/wp\/v2\/new_tags?post=18243"},{"taxonomy":"series","embeddable":true,"href":"https:\/\/www.editage.com\/insights\/wp-json\/wp\/v2\/series?post=18243"},{"taxonomy":"subject","embeddable":true,"href":"https:\/\/www.editage.com\/insights\/wp-json\/wp\/v2\/subject?post=18243"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}